7/8 (88%) methods found mutually exclusive alterations in KRAS, NRAS or BRAF as a predictive biomarker, from which one, two and four methods proposed this marker in conjunction with tumour sidedness, CMS and across all patients, respectively (Supplementary Table 1). This evidence concerns the gene NRAS and neoplasm.